

Dermatology

Department	Indication	Drugs	Initiation requirements	Continuation requirements
Dermatology	Plaque Psoriasis Plaque Psoriasis pathway	<i>1st line:</i> Adalimumab <i>2nd line:</i> Etanercept Tildrakizumab Risankizumab Guselkumab Brodalumab Certolizumab <i>Less cost effective options:</i> Ixekizumab Secukinumab Ustekinumab Infliximab	- PASI & DLQI scores in line with NICE - All new patients require initiation form - All switched patients require initiation form	- Evidence of PASI/ DLQI reduction in line with NICE - Follow up form at 12 months - Ongoing continuation forms not required thereafter
Dermatology	Plaque Psoriasis (Orals) Plaque Psoriasis pathway	Apremilast Dimethyl fumarate	- PASI & DLQI scores in line with NICE - All new patients require initiation form - All switched patients require initiation form	- Evidence of PASI/ DLQI reduction in line with NICE - Follow up form at 12 months - Ongoing continuation forms not required thereafter
Dermatology	Atopic Dermatitis Atopic Dermatitis pathway	Dupilumab Baricitinib	- EASI & DLQI scores in line with NICE - All new patients require initiation form - All switched patients require initiation form	- Evidence of EASI/ DLQI reduction in line with NICE - Follow up form at 12 months - Ongoing continuation forms not required thereafter
Dermatology	Urticaria	Omalizumab	- UAS7 score in line with NICE - All new patients require initiation form - Max 6 month course then treatment must be stopped	- A repeat course may be indicated if relapse occurs - Evidence of previous response and relapse required via UAS7 scores - Repeat course form required - Max 6 month course then treatment must be stopped
Dermatology	Hand Eczema	Alitretinoin	- PGA & DLQI scores in line with NICE - All new patients require initiation form - Max 6 month course then treatment must be stopped	- A repeat course may be indicated if relapse occurs - Evidence of previous response and relapse required via PGA & DLQI scores - Repeat course form required - Max 6 month course then treatment must be stopped

Gastroenterology

Department	Indication	Drugs	Initiation requirements	Continuation requirements
Gastroenterology	Ulcerative colitis IBD pathway	Adalimumab Infliximab Golimumab Ustekinumab Vedolizumab Tofactinib	- All new patients require initiation form - All switched patients require initiation form	- Continuation forms not required for adalimumab and infliximab if doses within BSW policy - All other drugs require a continuation form every 12 months
Gastroenterology	Crohns disease IBD pathway	Adalimumab Infliximab Ustekinumab Vedolizumab	- All new patients require initiation form - All switched patients require initiation form	- Continuation forms not required for adalimumab and infliximab if doses within BSW policy - All other drugs require a continuation form every 12 months

Clinical Biochemistry

Department	Indication	Drugs	Initiation requirements	Continuation requirements
Clinical Biochemistry	Primary hypercholesterolaemia (heterozygous-familial and non-familial) and mixed dyslipidaemia PCSK9 pathway	Evolocumab Alirocumab	- All new patients require initiation form - All switched patients require initiation form	- Follow up form at 12 months - Ongoing continuation forms not required thereafter

Haematology

Department	Indication	Drugs	Initiation requirements	Continuation requirements
Haematology	Idiopathic thrombocytopenic purpura ITP pathway (Update in progress)	Eltrombopag Romiplostim	- All new patients require initiation form - All switched patients require initiation form	- Follow up form at 12 months - Ongoing continuation forms not required thereafter
Haematology	Thrombocytopenia in People with Chronic Liver Disease Needing a Planned Invasive Procedure	Avatrombopag Lusutrombopag	- All new patients require initiation form	- A repeat form may be indicated if surgery delayed

Ophthalmology

Department	Indication	Drugs	Initiation requirements	Continuation requirements
Ophthalmology	Wet AMD Ophthalmology pathway	Aflibercept Ranibizumab	- BCVA scores in line with NICE - All new patients require initiation form - All switched patients require initiation form	- Current BCVA score to evidence no persistent deterioration in visual acuity - Follow up form at 12 months - Ongoing continuation forms not required thereafter
Ophthalmology	DMO Ophthalmology pathway	Aflibercept Ranibizumab Dexamethasone Fluocinolone	- All new patients require initiation form - All switched patients require initiation form	- Continuation forms not required
Ophthalmology	BRVO CRVO Ophthalmology pathway	Aflibercept Ranibizumab Dexamethasone	- All new patients require initiation form - All switched patients require initiation form	- Continuation forms not required
Ophthalmology	CNV Ophthalmology pathway	Aflibercept Ranibizumab	- All new patients require initiation form - All switched patients require initiation form	- Continuation forms not required
Ophthalmology	Uveitis Ophthalmology pathway	<i>1st course:</i> Dexamethasone <i>2nd course following relapse:</i> Dexamethasone Fluocinolone acetonide <i>Maximum 2 implants commissioned per patient.</i>	- Only dexamethasone recommended by NICE as 1 st line for non-infectious uveitis. - All new patients require initiation form	- <i>Dexamethasone:</i> Single implant, but may be repeated after approximately 6 months. If a patient experiences a response to treatment followed subsequently by a loss in visual acuity. Repeat form required. - <i>Fluocinolone:</i> Single implant, indicated for relapse in uveitis i.e if the disease has responded well to a dexamethasone, clinician could consider fluocinolone instead of a 2 nd dexamethasone implant. Initiation form required.

Neurology

Department	Indication	Drugs	Initiation requirements	Continuation requirements
Neurology	Chronic Migraine Migraine pathway	Erenumab Galcanezumab Fremanezumab	- All new patients require initiation form - All switched patients require initiation form	- Follow up form at 4 months - Ongoing continuation forms not required thereafter

Rheumatology

Department	Indication	Drugs	Initiation requirements	Continuation requirements
Rheumatology	Moderate Rheumatoid Arthritis Moderate RA pathway	Adalimumab Etanercept Infliximab Filgotinib Rituximab only if contraindications to all other options	- DAS scores in line with NICE - All new patients require initiation form - All switched patients require initiation form	- Continuation forms not currently required